A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (AC4115321)

NCT01372410 PHASE2 COMPLETED Results posted

The purpose of this study is to further characterize the dose response of GSK573719 at doses of 15.6 micrograms (mcg) to 125 mcg once daily in patients with chronic obstructive pulmonary disease (COPD). Treatment with doses of GSK573719 dosed twice daily will also be included to further evaluate dosing frequency. Treatment with tiotropium (18 mcg) once daily via the Handihaler will be included as an active control. A placebo treatment will be included in order to evaluate absolute treatment effect of the different doses of GSK573719.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	COMPLETED
Enrolment	163
Start date	Fri Jul 01 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 27 2011 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pulmonary Disease, Chronic Obstructive

Interventions

• GSK573719
• GSK573719
• GSK573719
• GSK573719
• GSK573719
• GSK573719
• Tiotropium
• Placebo

Countries

United States